Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C

Area of Science:

• Hepatology
• Endocrinology
• Immunology

Background:

• Chronic hepatitis C (CHC) is a prevalent liver infection that can progress to severe liver damage.
• Combination therapy with pegylated interferon (PEG-IFN) and Ribavirin is a primary treatment for CHC.
• Thyroid dysfunction is a significant autoimmune adverse effect of this combination therapy.

Purpose of the Study:

• To review the pathogenesis, clinical manifestations, and outcomes of interferon-induced thyroid disease (IITD).
• To highlight the importance of monitoring thyroid function in CHC patients undergoing antiviral treatment.
• To discuss the predictive factors for developing IITD.

Main Methods:

• Review of existing literature on interferon-induced thyroid disease in chronic hepatitis C patients.
• Analysis of pathogenesis, clinical presentations, and treatment associations.
• Evaluation of predictive markers such as antithyroid antibodies and patient demographics.

Main Results:

• Thyroid dysfunction, particularly hypothyroidism, is the most frequent autoimmune side effect of PEG-IFN and Ribavirin therapy.
• Antithyroid antibodies and female sex are identified as predictors for IITD development.
• Early screening and monitoring of thyroid function are crucial for managing CHC patients.

Conclusions:

• Interferon-induced thyroid disease is a common complication of CHC antiviral therapy.
• Proactive screening for thyroid dysfunction, including antibody testing and thyroid function tests, is essential before, during, and after treatment.
• Informing patients about potential thyroid side effects is critical for adherence and management.